Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Standing On The Shoulders Of Giants: Could Arecor Enter The Race To Revolutionize Diabetes?

Executive Summary

A small Cambridge, UK-based company, which is more at home partnering with the pharma industry than competing with it, is readying its run into the diabetes space with its ultra-rapid acting insulin. Scrip talked to its CEO to about the company’s biggest year yet.

You may also be interested in...



Cipla Chief Calls For Invigorating Focus On Repurposed Drugs

Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.

Lilly’s Ultra Rapid Lispro Mealtime Insulin Sails Through Phase III, But Will It Be Enough?

With only slight potential advantages in some types of patients, ultra-rapid insulins will likely still need to compete on price to be more widely successful, analysts say.

Lilly Pays KeyBioscience $55m Up Front to Expand Its Early Diabetes Pipeline

Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel